Adebrelimab

SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development. This year, Hengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities. According to statistics, 94 Chinese research projects were selected for oral presentations at ASCO this year, including 12 late-breaking abstracts, marking the third consecutive year of growth. At 2026 ASCO Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies, underscoring the breadth of the company's oncology pipeline and ongoing investment in innovative drug development. As a leading innovative pharmaceutical company in China, Hengrui continues to focus on oncology research and drug development. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). These programs are supported by more than 10 technology platforms covering small molecules, ADCs, bispecific and multispecific antibodies, and degraders. Together, these platform-based R&D capabilities support a broad oncology pipeline encompassing multiple therapeutic approaches across different tumor types. Breast Cancer: New Data Support Multiple Emerging Treatment Strategies For triple-negative breast cancer, the HELEN-Trio 011 study led by Professor Zhenzhen Liu of Henan Cancer Hospital showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity. Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show Promise In the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second Affiliated Hospital of Zhejiang University School of Medicine demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with conventional chemotherapy, suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of liver cancer, the CARES-336 study, co-led by Academician Jia Fan from Zhongshan Hospital Affiliated to Fudan University and Professor Shukui Qin from Tsientang Institute for Advanced Study, has for the first time demonstrated that the "Camrelizumab + Apatinib" regimen combined with transarterial chemoembolization (TACE) significantly prolongs median PFS compared to TACE alone (by BIRC per mRECIST, 11.1 months vs. 8.3 months), supporting the potential use of this combination approach in patients with unresectable hepatocellular carcinoma (uHCC). Urological Cancers: Dual Breakthroughs in Prostate and Bladder Cancers The FUZUPRO study, led by Professor Dingwei Ye of Fudan University Shanghai Cancer Center, demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction. Supportive Cancer Care: Additional Evidence for New Antiemetic Drug The Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. These findings add to the growing body of clinical evidence supporting its use in supportive cancer care. Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs. Hengrui's expanding presence at the ASCO Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company's research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio. As oncology research continues to evolve globally, Hengrui remains focused on translating scientific innovation into potential clinical benefit for patients through sustained investment in research and development. SOURCE Hengrui Pharma 21% more press release views with Request a Demo

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of the drug, known as MK-2010, while four of nine patients responded to a higher dose. It’s the first data in humans revealed for MK-2010, which was developed by LaNova Medicines (Sino acquired LaNova in July 2025). The data remain early, but “in line with peers” in lung cancer, Leerink analyst Daina Graybosch wrote in a Sunday note to investors. — Max Gelman Biogen gets China rights to CD38 antibody: The company will pay TJ Biopharma $100 million upfront and up to $750 million in biobucks for the rights to felzartamab in Greater China. Biogen has billed the CD38-targeting antibody as a “pipeline in a product.” It’s currently in multiple Phase 3 trials for immune-mediated diseases such as IgA nephropathy and primary membranous nephropathy. Biogen will now have exclusive worldwide rights, after getting the ex-China rights from the acquisition of HI-Bio in 2024. — Nicole DeFeudis Hansoh shares early lung cancer data for B7-H3-directed ADC: The biotech’s risvutatug rezetecan combined with Jiangsu Hengrui Pharmaceuticals’ anti-PD-L1 drug adebrelimab achieved a 47.1% ORR in patients with advanced non-squamous non-small cell lung cancer. Results from the open-label Phase 1 trial in China were presented Monday at the American Association for Cancer Research annual meeting in San Diego. The risvutatug rezetecan regimen also attained a median PFS of 14 months. GSK acquired ex-China rights to the drug from Hansoh in a 2023 deal, which featured $185 million upfront . — Ayisha Sharma Monopar trumpets Phase 3 rare disease data: The biotech said its drug ALXN1840, designed to treat the rare genetic disorder Wilson’s disease, led to “higher rates of improvement and lower rates of worsening” when compared to standard of care. Monopar expects to file an FDA submission in mid-2026. ALXN1840 was originally developed by Alexion, and AstraZeneca culled the program in 2023 while taking a $244 million writedown. — Max Gelman Genmab terminates cancer drug from ProfoundBio: The company terminated a Phase 1/2 study for GEN1286, according to the federal clinical trials database, because of an “unfavorable benefit-risk profile.” Genmab had halted enrollment in the study earlier this year. Genmab acquired ProfoundBio for $1.8 billion in 2024. — Max Gelman Replimune further reduces headcount after FDA rejection: The Woburn, MA-based drugmaker expects to lay off 63 staffers through Friday, according to the state’s WARN tracker . That brings the company’s total number of staff cuts in April to more than 200. Earlier this month, Replimune received a CRL from the FDA for its skin cancer drug. — Ayisha Sharma Agenus touts positive data in gastroesophageal cancer: The Lexington, MA-based biotech company said 77% of patients who received its experimental antibodies botensilimab and balstilimab in combination with MiNK Therapeutics’ allo-iNKT cell therapy agenT-797 achieved disease control in a Phase 2 trial. Patients also received ramucirumab and paclitaxel. Those who were treated with an induction cycle before the full combination had longer progression-free survival, Agenus said, “supporting the potential importance of immune priming and treatment sequencing.” Agenus is developing botensilimab and balstilimab to work together against cancer, and the combination is currently in a Phase 3 trial in colorectal cancer. — Nicole DeFeudis Lumira Ventures’ fifth fund: The Canadian and US VC firm is targeting $200 million, or 275 million Canadian dollars, for its fifth fund. The firm invests in medical technology and biotech startups in North America. — Kyle LaHucik Mabwell eyes Hong Kong IPO next week: The Shanghai-based biotech expects to trade on the Hong Kong Stock Exchange later this month and is penciling in $1.18 billion Hong Kong dollars (about $150 million) in net proceeds from the float. Mabwell is familiar with US drug developers by way of partnerships with Aditum Bio and Alphabet’s Calico . The biotech has been listed on the Shanghai Stock Exchange since 2022. Its portfolio includes four commercialized products and 10 drug candidates, including ADCs, monoclonal antibodies and other modalities. — Kyle LaHucik Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.